04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
01:40 , Dec 30, 2016 |  BC Week In Review  |  Company News

Clinical Genomics sales and marketing update

Clinical Genomics launched its Colvera blood-based test in the U.S. to monitor the recurrence of colorectal cancer. Colvera is a PCR-based test that measures two epigenetically modified genes -- hyper-methylated cytosolic branched chain amino-acid transaminase...
07:00 , Aug 4, 2016 |  BC Innovations  |  Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
00:58 , Mar 24, 2016 |  BC Extra  |  Financial News

Diagnostics play Clinical Genomics raises $15M

Clinical Genomics Pty. Ltd. (North Ryde, Australia) closed a $15 million series A round led by Australian venture firm OneVentures. This year, Clinical Genomics plans to launch its Gemini test in the U.S. for post-surgical...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

2-Gene Colorectal Cancer Recurrence Test: Clinical trial data

An analysis of 120 patients with known colorectal recurrence status following resection of a primary tumor showed that Clinical Genomics’ 2-Gene Colorectal Cancer Recurrence Test had an overall sensitivity of 63% and specificity of 86%...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) IKAROS family zinc finger 1 (IKZF1; LYF1); IKZF3; cereblon (CRBN) In vitro studies identified degradation of IKZF1 and IKZF3 as the anticancer...
07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) IKAROS family zinc finger 1 (IKZF1) Genetic association studies suggest that deletions in IKZF1 could be used as a prognostic marker...